(S)-2-(Cyclobutylamino)-N-(3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)isonicotinamide Attenuates RANKL-Induced Osteoclast Differentiation by Inhibiting NF-κB Nuclear Translocation

Osteoporosis is a common skeletal disease; however, effective pharmacological treatments still need to be discovered. This study aimed to identify new drug candidates for the treatment of osteoporosis. Here, we investigated the effect of EPZ compounds, protein arginine methyltransferase 5 (PRMT5) in...

Descripción completa

Detalles Bibliográficos
Autores principales: Ding, Mina, Cho, Eunjin, Chen, Zhihao, Park, Sang-Wook, Lee, Tae-Hoon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10002170/
https://www.ncbi.nlm.nih.gov/pubmed/36901758
http://dx.doi.org/10.3390/ijms24054327

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10002170/
https://www.ncbi.nlm.nih.gov/pubmed/36901758
http://dx.doi.org/10.3390/ijms24054327

Ejemplares similares